ArticleFrontiers in oncology2025
Effectiveness and mechanisms of lymphocytes at different time points in predicting consolidation immunotherapy following adaptive chemoradiotherapy in locally advanced non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prognostic value of lymphocytes and their subsets at different stages of chemoradiotherapy and consolidation immunotherapy in patients with locally advanced non-small cell lung cancer (NSCLC). Methods: This retrospective analysis enrolled 139 patients with stage III NSCLC (median age 69 years; 95% male; 84.17% squamous cell carcinoma) who received adaptive chemoradiotherapy (CRT) and consolidation anti-PD-1 therapy (sintilimab). Paired samples t-tests were performed to evaluate differences in absolute lymphocyte counts (ALCs) at three time points: before radiotherapy, at the 20th fraction of radiotherapy, and 1 month after radiotherapy. Additionally, paired t-tests were used to compare lymphocyte subsets between the pre-radiotherapy period and 1 month post-radiotherapy. Univariate and multivariate Cox proportional hazards regression analyses were conducted to identify factors influencing progression-free survival (PFS) and overall survival (OS). The Kaplan-Meier analysis was employed to assess PFS and OS in patients stratified according to independent predictive factors associated with OS. Results: Statistically significant differences were observed in ALCs among the three time points before radiotherapy, at the 20th fraction of radiotherapy, and 1 month after radiotherapy (p < 0.05). Univariate and multivariate analyses identified ALCs at 1 month post-radiotherapy, ALC decrease (defined as the difference between pre-radiotherapy and the 20th fraction of adaptive radiotherapy), and ALC increase (defined as the difference between the 20th fraction and pre-radiotherapy) as independent predictors of OS (p < 0.05). The Kaplan-Meier curves demonstrated that patients with ALCs > 1.015 × 10 Conclusion: In patients with locally advanced NSCLC receiving chemoradiotherapy followed by consolidation immunotherapy, higher ALCs and elevated CD8+ T-cell counts at 1 month post-chemoradiotherapy are associated with improved overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.